Dashboard
Manage Tickers

STIM Neuronetics, Inc.

Nasdaq neurostar.com


$ 2.70 $ -0.19 (-6.6 %)    

Friday, 17-Oct-2025 19:59:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.69
$ 2.86
$ 2.66 x 1,624
$ 2.70 x 1,319
$ 2.68 - $ 2.94
$ 0.52 - $ 5.92
941,832
na
177.88M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 03-02-2021 12-31-2020 10-K
20 11-02-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 03-03-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-05-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/06/2025 21:06:27

new-york-medicaid-to-cover-neuronetics-tms-therapy-for-major-depressive-disorder-starting-october-2025
New York Medicaid To Cover Neuronetics' TM...
09/17/2025 12:41:56

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

canaccord-genuity-maintains-buy-on-neuronetics-lowers-price-target-to-7
Canaccord Genuity Maintains Buy on Neurone...
08/06/2025 18:12:22

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $...

neuronetics-affirms-fy2025-sales-guidance-of-149000m-155000m-vs-150673m-est
Neuronetics Affirms FY2025 Sales Guidance ...
08/05/2025 11:07:23

Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 mill...

neuronetics-sees-q3-sales-37000m-39000m-vs-38395m-est
Neuronetics Sees Q3 Sales $37.000M-$39.000...
08/05/2025 11:07:03

Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.

neuronetics-q2-eps-015-misses-008-estimate-sales-38108m-beat-36612m-estimate
Neuronetics Q2 EPS $(0.15) Misses $(0.08) ...
08/05/2025 11:06:14

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08)...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

neuronetics-publishes-real-world-data-showing-antidepressant-effects-of-neurostar-tms-in-adolescents-and-young-adults
Neuronetics Publishes Real-World Data Show...
07/30/2025 12:33:37

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...

neuronetics-appoints-steven-pfanstiel-as-cfo-effective-july-15-2025-reaffirms-q2-fy25-guidance-citing-integration-of-greenbrook-operations-and-continued-progress-across-key-growth-drivers
Neuronetics Appoints Steven Pfanstiel As C...
07/15/2025 11:33:50

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Stev...

neuronetics-set-to-join-russell-3000-index-and-russell-2000-index-effective-june-30-2025
Neuronetics Set To Join Russell 3000 Index...
06/02/2025 20:31:18

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/27/2025 12:10:46

neuronetics-sees-q2-revenue-of-36m---38m-vs-36690m-est
Neuronetics Sees Q2 Revenue Of $36M - $38M...
05/06/2025 11:16:44

neuronetics-q1-eps-021-misses-014-estimate-sales-3198m-beat-2907m-estimate
Neuronetics Q1 EPS $(0.21) Misses $(0.14) ...
05/06/2025 11:12:18

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.14)...

Core News & Articles
Earnings Scheduled For May 6, 2025
05/06/2025 08:32:41

neuronetics-reports-updated-q4-results-net-loss-033
Neuronetics Reports Updated Q4 Results; Ne...
03/27/2025 20:38:58

Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024a $0.6 million reduction in the 2024 bonus accrual that...

canaccord-genuity-maintains-buy-on-neuronetics-raises-price-target-to-8
Canaccord Genuity Maintains Buy on Neurone...
03/05/2025 21:21:17

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $...

citizens-capital-markets-maintains-market-outperform-on-neuronetics-raises-price-target-to-7
Citizens Capital Markets Maintains Market ...
03/05/2025 15:21:45

Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:STIM) with a Market Outperform and raises the ...

neuronetics-expects-q1-revenue-of-28m-30m-vs-2102m-est-fy25-revenue-of-145m-155m-vs-9355m-est
Neuronetics Expects Q1 Revenue Of $28M-$30...
03/04/2025 12:08:20

Business OutlookFor the first quarter of 2025, the Company expects total worldwide revenue between $28.0 million and $30.0 mill...

neuronetics-q4-2024-gaap-eps-033-misses-017-estimate-sales-22493m-beat-19634m-estimate
Neuronetics Q4 2024 GAAP EPS $(0.33) Misse...
03/04/2025 12:05:33

earnings-scheduled-for-march-4-2025
Earnings Scheduled For March 4, 2025
03/04/2025 08:32:12

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION